Back to mobile site

Piper Sandler Reiterates Overweight Rating on Monte Rosa Therapeutics (GLUE)

May 30, 2024 7:42 AM EDT Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $16.00 price target on Monte Rosa Therapeutics (NASDAQ: GLUE).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login